Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity. Academic Article uri icon

abstract

  • OBJECTIVES: The focus of the present research is to develop printlet formulations of pyrimethamine (PMT). METHODS: Printlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon VA 64, polyvinylpyrrolidone, and disintegrant. RESULTS: Laser scanning speed, Kollidon VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p<0.05). Dissolution was almost 100% in 30min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p>0.05). CONCLUSION: Clinical performance of the printlets would be similar to the compressed tablets.

published proceedings

  • Expert Opin Drug Deliv

author list (cited authors)

  • Rahman, Z., Khuroo, T., Mohamed, E. M., Dharani, S., Kayalar, C., Kuttolamadom, M. A., Sangar, L. O., & Khan, M. A.

citation count

  • 0

complete list of authors

  • Rahman, Ziyaur||Khuroo, Tahir||Mohamed, Eman M||Dharani, Sathish||Kayalar, Canberk||Kuttolamadom, Mathew A||SangarĂ©, Lamba Omar||Khan, Mansoor A

publication date

  • February 2023